Management of antipsychotic-related weight gain
نویسندگان
چکیده
منابع مشابه
Youth, Caregiver, and Prescriber Experiences of Antipsychotic-Related Weight Gain
Objectives. To explore the lived experience of youth, caregivers, and prescribers with antipsychotic medications. Design. We conducted a qualitative interpretive phenomenology study. Youth aged 11 to 25 with recent experience taking antipsychotics, the caregivers of youth taking antipsychotics, and the prescribers of antipsychotics were recruited. Subjects. Eighteen youth, 10 caregivers (parent...
متن کاملMechanisms and genetics of antipsychotic-associated weight gain.
Antipsychotic medications, which comprise one of the most widely prescribed medication classes, have proven effective in many psychiatric conditions. However, these agents can also be associated with obesity and other metabolic abnormalities, the mechanisms of which have been partially elucidated. We review here the current state of knowledge of the effects of these medications on weight and ap...
متن کاملContingency management for the treatment of antipsychotic-induced weight gain: a randomized controlled pilot study.
OBJECTIVE Weight gain is common for individuals with serious mental illness (SMI) receiving antipsychotic drug therapy. Contingency management (CM) is a behavioral intervention that rewards positive performance and has demonstrated effectiveness in reducing drug use in SMI populations. This study evaluated the feasibility of using CM to promote weight loss in individuals with SMI over 8 weeks. ...
متن کاملMetformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
The seriously mentally ill have significantly more cardiovascular risk factors, receive less appropriate medical care, and die on average 15 to 30 years earlier than the general population, mostly because of cardiovascular disorders (1). Reasons for this physical health disparity are complex and include unhealthy lifestyle behaviors, illness-related effects (including poverty, negative symptoms...
متن کاملMC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?
Weight gain is a therapy limiting and very frequent adverse effect of many second-generation antipsychotic (SGA) drugs. The human melanocortin four receptor (MC4R) is a very promising candidate gene possibly influencing SGA-related weight gain. The rs489693 polymorphism near the MC4R gene was associated with SGA-related weight gain in a genome-wide association study. We tried to replicate these...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Neurotherapeutics
سال: 2010
ISSN: 1473-7175,1744-8360
DOI: 10.1586/ern.10.85